Table 4.
Changes in Body Composition and Bone Mineral Density Outcomes Following the Intervention.
| Vibration Group (Mean ±
SD) |
Control Group (Mean ±
SD) |
Adjusted Group Difference in Mean Changea |
||||
|---|---|---|---|---|---|---|
| Body Composition | Pre | Post | Pre | Post | Mean (95% CI) | P |
| Waist to hip ratio | 0.83 ± 0.07 | 0.82 ± 0.06 | 0.83 ± 0.67 | 0.83 ± 0.70 | 0.012 (–0.30, 0.55) | .548 |
| Whole body mass, kg | 75.1 ± 13.3 | 74.4 ± 12.3 | 75.6 ± 14.3 | 75.6 ± 14.2 | −0.1 (–2.7, 2.4) | .912 |
| Whole body lean mass, kg | 41.4 ± 5.3 | 41.3 ± 5.4 | 43.3 ± 5.7 | 43.0 ± 5.7 | 0.3 (–0.9, 1.6) | .573 |
| Appendicular lean mass, kg | 16.5 ± 2.4 | 16.2 ± 2.4 | 17.4 ± 2.5 | 17.2 ± 2.4 | 0.1 (–0.9, 1.1) | .820 |
| Whole body fat mass, kg | 30.7 ± 8.3 | 31.0 ± 7.5 | 30.9 ± 9.6 | 31.1 ± 9.3 | 0.1 (–1.0, 1.2) | .803 |
| Whole body fat percentage, % | 40.9 ± 4.6 | 41.3 ± 4.1 | 40.2 ± 5.7 | 40.6 ± 5.3 | 0.1 (–1.2, 1.4) | .890 |
| Trunk fat mass, kg | 14.6 ± 4.6 | 14.9 ± 4.1 | 14.6 ± 5.4 | 14.7 ± 5.3 | −0.2 (–1.1, 0.7) | .607 |
a
Adjusted for baseline value and time on aromatase inhibitor at baseline.